Related Experiment Video
Updated: Jun 9, 2025
00:05
Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head
Published on: January 3, 2020
8.1K
Metastatic insulinoma-outcomes in the current era
Umesh Masharani1, Sheila Lindsay2, Farhana Moon2
1Department of Medicine, University of California, San Francisco, CA 94143, United States.
The Oncologist
|October 30, 2024
Summary
Multimodal treatments for metastatic insulinoma effectively manage hypoglycemia and significantly extend survival, challenging previous assumptions about patient outcomes.
Area of Science:
- Oncology
- Endocrinology
- Medical Research
Background:
- Metastatic insulinoma historically presents with hypoglycemia and poor prognosis.
- Multimodal interventions show promise in neuroendocrine tumor management.
Purpose of the Study:
- To evaluate the effectiveness of multimodal interventions in metastatic insulinoma.
- To assess the impact on survival and hypoglycemia control.
Main Methods:
- Retrospective analysis of 14 metastatic insulinoma patients (2006-2023).
- Review of diverse treatments: surgery, liver-directed therapies, somatostatin analogs, targeted agents, chemotherapy, and radiation.
Main Results:
- Median survival was 8.2 years, significantly longer than the historical 2 years.
- Seven patients are alive between 1.2-12.3 years post-diagnosis.
- Hypoglycemia was effectively managed and did not cause mortality.
Conclusions:
- Multimodal interventions improve outcomes for metastatic insulinoma.
- These treatments offer extended survival and effective hypoglycemia management.
- Findings challenge prior expectations of clinical outcomes in this patient group.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
148
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
148
01:15Hypoglycemia and Glucagon
153
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
153
01:22Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K